Department of Hematology, Xinqiao Hospital and State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, People's Republic of China.
Anticancer Drugs. 2019 Oct;30(9):948-952. doi: 10.1097/CAD.0000000000000811.
Pegylated liposomal doxorubicin (Peg-Dox) treatment resulted in a good outcome for patients with lymphoma and multiple myeloma, with reduced cardiotoxicity and an improved pharmacokinetic profile when compared to those of conventional doxorubicin. However, the use of Peg-Dox in myeloid neoplasms remains poorly studied. In this study, we first tested the role of Peg-Dox in the killing of myeloid cell lines and of primary myeloid leukemia cells. Then, a Peg-Dox-based protocol was used to treat patients with myeloid neoplasms. The results showed that the Peg-Dox and Peg-Dox-based protocols had a similar killing ability in myeloid cell lines and in primary myeloid leukemia cells compared to that of conventional doxorubicin. The complete remission rate was 87.5% and 100% for patients with refractory/relapsed acute myeloid leukemia and myelodysplastic syndrome with excess blasts, respectively, after treatment with Peg-Dox. All patients developed grade 3 or 4 hematological toxicity and recovered approximately 2 weeks after completing chemotherapy. No deaths or other severe complications were reported. Our results showed that Peg-Dox can be used in the treatment of myeloid neoplasms with high rates of complete remission and with mild complications.
聚乙二醇脂质体阿霉素（Peg-Dox）治疗淋巴瘤和多发性骨髓瘤患者的效果良好，与传统阿霉素相比，其心脏毒性降低，药代动力学特征改善。然而，Peg-Dox 在髓系肿瘤中的应用研究甚少。本研究首先检测了 Peg-Dox 在杀伤髓系细胞系和原发性髓系白血病细胞中的作用。然后，采用基于 Peg-Dox 的方案治疗髓系肿瘤患者。结果表明，与传统阿霉素相比，Peg-Dox 和基于 Peg-Dox 的方案在髓系细胞系和原发性髓系白血病细胞中具有相似的杀伤能力。接受 Peg-Dox 治疗的难治/复发急性髓系白血病和伴原始细胞过多的骨髓增生异常综合征患者的完全缓解率分别为 87.5%和 100%。所有患者均出现 3 级或 4 级血液学毒性，在完成化疗后约 2 周恢复。未报告死亡或其他严重并发症。我们的研究结果表明，Peg-Dox 可用于治疗完全缓解率高且并发症轻微的髓系肿瘤。
